Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer
Status:
Terminated
Trial end date:
2018-11-02
Target enrollment:
Participant gender:
Summary
The primary objective will be to assess overall response rate of nivolumab in patients with
metastatic or locally advanced adrenocortical carcinoma. Nivolumab was recently approved by
U.S. Food and Drug Administration (FDA) for the treatment of advanced melanoma, non-small
cell lung cancer and renal cell carcinoma. It is considered investigational for the treatment
of advanced or refractory adrenocortical carcinoma. "Investigational" means that the drug is
not approved by the USFDA or not approved for the indication under investigation. Nivolumab
could shrink adrenocortical carcinoma but it could also cause side effects. Researchers hope
to learn if the study drug will shrink the cancer and hopefully to relieve symptoms that are
related to the cancer.